(R)-methyl-(1-naphthalen-2-yl-ethyl)-amine | 945978-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (R)-methyl-(1-naphthalen-2-yl-ethyl)-amine
• 英文别名: N-methyl-(R)-(+)-1-(2-naphthyl)ethylamine；methyl[(1R)-1-(naphthalen-2-yl)ethyl]amine；(1R)-N-methyl-1-naphthalen-2-ylethanamine
• CAS: 945978-58-5
• 化学式: C₁₃H₁₅N
• 分子量: 185.269
• InChiKey: VRPIUODNLOVPNH-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-氨基-4,6-二氯嘧啶 、 (R)-methyl-(1-naphthalen-2-yl-ethyl)-amine 在 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.33h， 生成 (R)-6-chloro-N-4-methyl-N-4-(1-napthalen-2-yl-ethyl)-pyrimidine-2,4-diamine
  参考文献：
  名称：

  Multicyclic amino acid derivatives and methods of their use

  摘要：

  公式I和II的化合物已被披露，以及包含它们的组合物和它们的使用方法，用于治疗、预防和管理与血清素介导的疾病和紊乱：

  公开号：

  US20070191370A1
• 作为产物：
  描述：

  2-萘乙酮 在 C₃₄H₃₇FeN₃O₂Si 、 频那醇硼烷 作用下， 以 乙醇 、 正己烷 、 甲苯 为溶剂， 反应 152.0h， 生成 (R)-methyl-(1-naphthalen-2-yl-ethyl)-amine
  参考文献：
  名称：

  用3d金属催化处理N-烷基亚胺：高对映选择性铁催化的α-手性胺的合成。

  摘要：

  易于活化的烷基铁预催化剂可有效催化N-烷基亚胺的高度对映选择性氢硼化。使用手性双（恶唑啉基亚甲基）异二氢吲哚钳配体，各种无环N-烷基亚胺的不对称还原提供了相应的α-手性胺，收率极高，ee高达99％以上。药物芬迪林和Tecalcet的合成进一步证明了该贱金属催化体系的适用性。

  DOI：

  10.1002/anie.202006557

文献信息

• COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES
  申请人：Ghosh Arun K.

  公开号：US20110269834A1

  公开（公告）日：2011-11-03

  Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).

  本文描述了化合物和组合物，以及使用这些化合物和组合物治疗呼吸道疾病和疾病，如严重急性呼吸综合征（SARS）的方法。
• PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140243338A1

  公开（公告）日：2014-08-28

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Roivant Sciences GmbH

  公开号：US10946018B2

  公开（公告）日：2021-03-16

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及的螺环化合物是色氨酸羟化酶（TPH），特别是同工酶 1（TPH1）的抑制剂，可用于治疗与外周血清素相关的疾病或失调，例如包括胃肠道、心血管、肺、炎症、代谢和低骨量疾病，以及血清素综合征和癌症。
• Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors
  作者：Haihong Jin、Giovanni Cianchetta、Arokiasamy Devasagayaraj、Kunjian Gu、Brett Marinelli、Lakshman Samala、Sheldon Scott、Terry Stouch、Ashok Tunoori、Ying Wang、Yi Zang、Chengmin Zhang、S. David Kimball、Alan J. Main、Zhi-Ming Ding、Weimei Sun、Qi Yang、Xiang-Qing Yu、David R. Powell、Alan Wilson、Qingyun Liu、Zhi-Cai Shi

  DOI：10.1016/j.bmcl.2009.07.005

  日期：2009.9

  Tryptophan hydroxylase (TPH) is a key enzyme in the synthesis of serotonin. As a neurotransmitter, serotonin plays important physiological roles both peripherally and centrally. Here we describe the discovery of substituted triazines as a novel class of tryptophan hydroxylase inhibitors. This class of TPH inhibitors can selectively reduce serotonin levels in murine intestine after oral administration without affecting levels in the brain. These TPH inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome. (C) 2009 Elsevier Ltd. All rights reserved.
• SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF
  申请人：EICKMEIER Christian

  公开号：US20100204160A1

  公开（公告）日：2010-08-12

  The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R 1 to R 15 , A, B, L, i as well as X 1 -X 4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.